Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

NASDAQ TTNP opened at $3.71 on Monday. Titan Pharmaceuticals has a 1 year low of $3.51 and a 1 year high of $14.80. The stock’s fifty day moving average price is $4.62 and its 200 day moving average price is $5.59.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.